An Iongen Therapeutics Co. Ltd. patent reports transient receptor potential vanilloid 3 (TRPV3) receptor antagonists that are potentially useful for the treatment of acne, diabetes, anxiety, gastrointestinal, inflammatory and respiratory disorders, neurodegeneration and obesity, among others.

Jiangsu Vcare Pharmatech Co. Ltd. has created new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor α (ER-α)-binding moiety through a linker. They are reported to be useful for the treatment of cancer and infections.

Acrivon Therapeutics Inc. has identified new pyrimidine carboxamide compounds acting as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer.

Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described oxime-containing compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, transplant rejection and neurodegeneration, among others.

Researchers at Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM) and Université Côte d'Azur have divulged amidinourea derivatives reported to be useful for the treatment of cancer, in particular for BRAF inhibitor-resistant melanoma.

Merck Sharp & Dohme LLC has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.

Frontier Medicines Corp. has synthesized GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Acrivon Therapeutics Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

RTI International has described cannabinoid CB1 receptor antagonists reported to be useful for the treatment of metabolic syndrome, binge-eating disorder, Prader-Willi syndrome, alcoholism, nicotine dependence and cannabis abuse.